Three-dimensional Imaging Reveals Immune-driven Tumor-associated High Endothelial Venules as a Key Correlate of Tumor Rejection Following Depletion of Regulatory T Cells.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
15 12 2022
Historique:
entrez: 27 1 2023
pubmed: 28 1 2023
medline: 28 1 2023
Statut: ppublish

Résumé

High endothelial venules (HEV) are specialized post capillary venules that recruit naïve T cells and B cells into secondary lymphoid organs (SLO) such as lymph nodes (LN). Expansion of HEV networks in SLOs occurs following immune activation to support development of an effective immune response. In this study, we used a carcinogen-induced model of fibrosarcoma to examine HEV remodeling after depletion of regulatory T cells (Treg). We used light sheet fluorescence microscopy imaging to visualize entire HEV networks, subsequently applying computational tools to enable topological mapping and extraction of numerical descriptors of the networks. While these analyses revealed profound cancer- and immune-driven alterations to HEV networks within LNs, these changes did not identify successful responses to treatment. The presence of HEV networks within tumors did however clearly distinguish responders from nonresponders. Finally, we show that a successful treatment response is dependent on coupling tumor-associated HEV (TA-HEV) development to T-cell activation implying that T-cell activation acts as the trigger for development of TA-HEVs which subsequently serve to amplify the immune response by facilitating extravasation of T cells into the tumor mass.

Identifiants

pubmed: 36704666
doi: 10.1158/2767-9764.CRC-21-0123
pmc: PMC7614106
mid: EMS159490
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1641-1656

Subventions

Organisme : Breast Cancer Now
ID : 2019DECPR1377
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209213
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A21200
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom

Références

Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404866
Nat Commun. 2015 May 13;6:7114
pubmed: 25968334
J Pathol. 2018 Jun;245(2):209-221
pubmed: 29603739
Microcirculation. 1996 Sep;3(3):287-300
pubmed: 8930886
Elife. 2020 Jan 28;9:
pubmed: 31990272
Oncotarget. 2017 Nov 3;8(59):99207-99208
pubmed: 29245888
Nat Biomed Eng. 2017 Oct;1(10):796-806
pubmed: 31015588
J Exp Med. 1972 Oct 1;136(4):697-714
pubmed: 5056671
Adv Anat Embryol Cell Biol. 2014;214:81-91
pubmed: 24276888
J Immunol. 2005 Jun 1;174(11):7217-25
pubmed: 15905567
Blood. 2001 Jan 1;97(1):192-7
pubmed: 11133760
Nat Rev Immunol. 2003 Nov;3(11):867-78
pubmed: 14668803
Cancer Cell. 2022 Mar 14;40(3):318-334.e9
pubmed: 35120598
Nature. 2011 Nov 13;479(7374):542-6
pubmed: 22080953
Blood. 2010 Jun 10;115(23):4725-33
pubmed: 20185585
Nature. 2007 Dec 6;450(7171):903-7
pubmed: 18026089
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
pubmed: 9636188
Angiogenesis. 2021 Nov;24(4):719-753
pubmed: 33956259
Immunity. 2001 Feb;14(2):111-21
pubmed: 11239444
Sci Immunol. 2019 Oct 18;4(40):
pubmed: 31628161
Nat Methods. 2020 Apr;17(4):442-449
pubmed: 32161395
Cancer Cell. 2016 Mar 14;29(3):285-296
pubmed: 26977880
J Immunol. 2004 Nov 15;173(10):6161-8
pubmed: 15528353
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Cell Rep. 2019 Mar 12;26(11):3116-3131.e5
pubmed: 30865898
Nat Methods. 2007 Jan;4(1):31-3
pubmed: 17143281
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
Immunity. 1994 Sep;1(6):447-56
pubmed: 7895156
J Immunol. 2010 Apr 15;184(8):4247-57
pubmed: 20231692
Cancer Res. 2012 Nov 1;72(21):5473-82
pubmed: 22962270
J Immunol. 2014 May 1;192(9):4153-63
pubmed: 24659690
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
J Exp Med. 1977 Jan 1;145(1):31-44
pubmed: 830789
Cell. 2019 Dec 12;179(7):1661-1676.e19
pubmed: 31835038
Sci Rep. 2019 Apr 4;9(1):5624
pubmed: 30948791
Front Immunol. 2017 Dec 19;8:1830
pubmed: 29312327
Nat Immunol. 2004 Feb;5(2):141-9
pubmed: 14704792
Nat Methods. 2019 Sep;16(9):870-874
pubmed: 31384047
Cancer Immunol Res. 2020 Feb;8(2):192-202
pubmed: 31831634
J Immunol Methods. 2016 Apr;431:1-10
pubmed: 26844990
Cancer Res. 2006 Apr 1;66(7):3355-8, discussion 3358-9
pubmed: 16585152
Cell Rep. 2020 Jan 21;30(3):714-724.e5
pubmed: 31968248
Methods Cell Biol. 2021;163:59-75
pubmed: 33785169
J Exp Med. 2013 Mar 11;210(3):465-73
pubmed: 23420877
Trends Cancer. 2021 Mar;7(3):214-225
pubmed: 33132107
Nat Neurosci. 2019 Feb;22(2):317-327
pubmed: 30598527
Cancer Immunol Res. 2020 Dec;8(12):1520-1531
pubmed: 33023965
Cell. 2015 Feb 26;160(5):963-976
pubmed: 25723170
Nature. 2014 Jun 19;510(7505):407-411
pubmed: 24919154
Br J Cancer. 2007 Jun 18;96(12):1849-54
pubmed: 17565340
Cancer Res. 2006 Oct 1;66(19):9617-24
pubmed: 17018619
Cancer Discov. 2021 Apr;11(4):838-857
pubmed: 33811120
J Immunol. 2008 Sep 15;181(6):3887-96
pubmed: 18768843
Nat Immunol. 2007 Feb;8(2):191-7
pubmed: 17136045
J Exp Med. 1996 Nov 1;184(5):1781-90
pubmed: 8920866
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33093155
Nat Rev Cancer. 2021 Nov;21(11):718-730
pubmed: 34331034
Immunity. 2005 Nov;23(5):539-50
pubmed: 16286021
Front Immunol. 2012 Sep 07;3:282
pubmed: 22973277
Nat Commun. 2020 Jul 30;11(1):3798
pubmed: 32732867
J Exp Med. 2006 Aug 7;203(8):1903-13
pubmed: 16831898
Cancer Immunol Res. 2017 Nov;5(11):1005-1015
pubmed: 28947544
Cancer Res. 2012 Aug 15;72(16):3987-96
pubmed: 22869585
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
J Am Soc Nephrol. 2017 Feb;28(2):452-459
pubmed: 27487796
Oncoimmunology. 2012 Sep 1;1(6):829-839
pubmed: 23162750
Nat Immunol. 2017 Nov;18(11):1207-1217
pubmed: 28892469
Sci Rep. 2015 Nov 16;5:16534
pubmed: 26567707
J Exp Med. 2007 Apr 16;204(4):735-45
pubmed: 17371928
Cancer Res. 2011 Sep 1;71(17):5678-87
pubmed: 21846823
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Am J Pathol. 1975 Oct;81(1):131-60
pubmed: 1101703
Nat Rev Immunol. 2012 Nov;12(11):762-73
pubmed: 23018291

Auteurs

Stefan Milutinovic (S)

Systems Immunity University Research Institute, Henry Wellcome Building, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Jun Abe (J)

Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland.

Emma Jones (E)

Systems Immunity University Research Institute, Henry Wellcome Building, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Inken Kelch (I)

School of Biological Sciences, University of Auckland, Auckland, New Zealand.

Kathryn Smart (K)

Systems Immunity University Research Institute, Henry Wellcome Building, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Sarah N Lauder (SN)

Systems Immunity University Research Institute, Henry Wellcome Building, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Michelle Somerville (M)

Systems Immunity University Research Institute, Henry Wellcome Building, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Carl Ware (C)

Laboratory of Molecular Immunology, Sanford Burnham Prebys, La Jolla, California.

Andrew Godkin (A)

Systems Immunity University Research Institute, Henry Wellcome Building, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Jens V Stein (JV)

Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland.

Gib Bogle (G)

Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand.

Awen Gallimore (A)

Systems Immunity University Research Institute, Henry Wellcome Building, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH